FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 624 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR New Safety Signal for Use of Ibrutinib in Combination with Rituximab... September 15, 2021 A Propensity Score Matched Study Supports the Use of Allogeneic HSCT... May 12, 2023 Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney Cancer March 19, 2019 Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows December 13, 2018 Load more HOT NEWS Sofi Leota Was Diagnosed With Breast Cancer At 23. Two Years... Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... K9 Police Officer In Berlin Beats Breast Cancer For Second Time Breast Cancer Survivor is Swimming the English Channel to Benefit Mental...
